C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
GDNSF Equity

GDNSF

OTCMKTS · GDNSF

$9.78
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 1/5
50/100 composite
Fundamentals66
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Vireo Growth earns a Neutral rating with a 49.8 composite score and low 1/5 conviction. Fundamentals provide the principal support at 66.0, driven by strong operating-margin and revenue-growth subscores, alongside positive EBITDA. Regulatory contributes a middling 49.0, reflecting a neutral U.S. jurisdiction posture and weak filing cadence despite no enforcement hits. Market performance scores 40.0 because institutional pricing feeds contain no available quote, limiting price-based confirmation. Editorial registers 30.0, with neither newsroom nor brief activity in CIN newsroom coverage. The resulting pillar mix supports balance rather than a directional call.

Licensed fundamentals data show year-over-year revenue growth of 26.2%, a clear positive underpinning for the fundamentals pillar. The 19.8% operating margin and $16.1 million of EBITDA reinforce operating progress, while the 21.3% gross margin remains comparatively less compelling within the pillar breakdown. The financial condition remains stretched because net income is negative by $23.9 million; positive EBITDA does not erase the bottom-line loss or establish a clear liquidity cushion. The company’s roughly $56.7 million market capitalization also limits the fundamentals contribution through a weaker size-tier subscore. Primary regulatory filings show no dated latest filing in the supplied record, no regulatory events across either the latest 90-day or 180-day periods, and no enforcement hits. That combination explains the solid enforcement subscore but weak cadence assessment.

The most credible rerating catalyst sits within fundamentals, the strongest pillar. Sustained revenue expansion paired with preservation of the 19.8% operating margin would validate the high revenue-growth and operating-margin subscores, improve confidence in EBITDA durability, and create a pathway above Neutral. Gross-margin expansion would broaden that support, while continued net losses would keep the stretched financial condition central to the rating. Regulatory, market, and editorial pillars currently offer little incremental momentum because filing cadence is limited, a quote is unavailable, and coverage activity is absent. The single most important signal to watch is whether the next primary regulatory filing confirms continued revenue growth while maintaining positive operating profitability.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
Headquarters
209 South 9th St., Minneapolis, MN 55402
Phone
(844)484-7366
CEO
John Mazarakis
CFO
Tyson Macdonald
SEC CIK
0001771706
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$56.7M
Enterprise value
$141.2M
Price to book
1.22
Price to sales
0.61
EV / EBITDA
6.29
Revenue (TTM)
$93.1M
Gross profit (TTM)
$19.8M
EBITDA
$16.1M
Operating margin
19.8%
Profit margin
-25.6%
Rev growth YoY
26.2%
Return on equity
-1890.8%
Return on assets
5.3%
EPS (TTM)
$-0.17
EPS est. current year
$-0.12
Wall St. target price
$0.55
Shares outstanding
112.3M
Insider ownership
17.4%
Institutional ownership
15.3%
Beta
1.42
Full-time employees
385
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for GDNSF (GDNSF)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for GDNSF (GDNSF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for GDNSF are maintained by Cannabis Investor News and refreshed throughout the trading day.